Current report No. 25/2019

Date prepared: 2019-08-19

Abbreviated name of the issuer: MABION S.A.

Subject: Obtaining the GMP certificate for the Complex in Konstantynow Lodzki in the field of manufacturing a medicinal product

Legal basis: Article 17, paragraph 1 MAR – confidential information

Content of the report:

The Management Board of Mabion S.A. ("Company") informs that on August 19, 2019 it received information, that the Company obtained, as a result of an inspection that had been carried out by the Main Pharmaceutical Inspector ("GIF"), the GMP certificate (Good Manufacturing Practice) for the Scientific Complex -Industrial Medical Biotechnology Mabion S.A. in Konstantynow Lodzki in the following manufacturing operations: production of sterile forms of biotechnology products, quality control research, batch release and packaging of medicinal products.

This is the second GMP certificate obtained by the Company as a result of a GIF inspection commissioned by the European Medicines Agency (EMA) within the assessment of the application for the admission of the MabionCD20 drug by the Company.

The company informed about obtaining the first GMP certificate - in the scope of manufacturing the active substance (Rituximab) in the current report No. 21/2019 of July 23, 2019

The present GMP certificate confirms that the Company conducts production processes in accordance with GMP principles in the abovementioned range. The certificate is valid for 3 years from the date of the last day of inspection (i.e. 17 May 2019).
The obtained GMP certificates are necessary for the manufacture, registration and commercialization of MabionCD20 drug, however obtaining GMP certificates does not guarantee product approval by EMA.

All the information about future GMP certifications that are becoming standard while the development of the Company's business and as such will not constitute confidential information will only be provided in periodic reports.